[Treatment of hepatocellular carcinoma with one-shot arterial infusion of mitomycin C].
Survival period of 28 cases with unresectable hepatocellular carcinoma treated with transhepatic arterial one-shot infusion of 30 mg mitomycin C (MMC) were retrospectively reviewed from the standpoint of hepatic angiographic findings, scintigraphic existence of liver cirrhosis and changes of AFP value. As the result, 17(61%) of 28 cases survived 6 months after treatment. As to the angiographic findings, no remarkable differences on the survival period was noted in both of less and/or more than 50% of the tumor extent occupied on hepatic angiogram, and relatively long-term survivors were seen in the cases without A-V shunt and invasion of portal veins. Concerning association with liver cirrhosis, the survival period was not dependent on the presence of liver cirrhosis on the scintigrams. Regarding the changes of AFP value before and after treatment, no survivor over 6 months was encountered in the cases which revealed an increasing value of AFP. It may be considered that hepatic arterial one-shot infusion of MMC should be attempted in the unresectable and advanced hepatocellular carcinoma, even though palliative treatment.
D000328:Adult; D000368:Aged; D000792:Angiography; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial; D008103:Liver Cirrhosis / Q000150:complications; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage*; D000509:alpha-Fetoproteins / Q000032:analysis
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D000509:alpha-Fetoproteins; D016685:Mitomycin